IDRx is a clinical-stage biopharmaceutical company based in Plymouth, Massachusetts, focused on revolutionizing cancer treatment through precision combination therapies. Founded in 2022, IDRx aims to enhance patient outcomes with intelligently designed solutions tailored to target cancer more effectively.
National Ranking17768th
in United States Regional Ranking19394th
in North America Global Ranking49382nd
worldwide Rankings by